When will a generic version of Daptomycin be available?
Daptomycin is a powerful antibiotic used to treat various bacterial infections, including skin and soft tissue infections, pneumonia, and endocarditis. Currently, Daptomycin is available under the brand name Cubicin, which is manufactured by Pfizer [1]. However, with the patent expiry, other pharmaceutical companies may develop generic versions.
Who is working on a generic version of Daptomycin?
Cubist Pharmaceuticals (acquired by Merck & Co.) held the patent for Daptomycin, but the patent expired in 2015. This allowed other pharmaceutical companies to develop generic versions of the drug. According to recent reports, several companies, including Teva Pharmaceuticals, Mylan, and Sandoz, are working on generic versions of Daptomycin [2].
What is the status of the generic development?
The development of generic Daptomycin is ongoing, but the exact timeline for approval and availability is unclear. DrugPatentWatch.com, a leading source of pharmaceutical patent information, indicates that several companies have filed Abbreviated New Drug Applications (ANDAs) with the FDA for generic versions of Daptomycin [3]. However, the FDA review process can take several years, and the launch of generic versions may be delayed until 2025 or later.
What implications does a generic version of Daptomycin have for patients?
A generic version of Daptomycin could lead to lower prices and increased availability of the antibiotic, making it more accessible to patients. However, patients should consult their healthcare providers to determine the suitability of a generic version of Daptomycin for their specific needs.
Sources:
[1] Pfizer. 2022. Cubicin (daptomycin) Prescribing Information. https://www.pfizer.com/medicine/cubicin.
[2] Bloomberg. 2022. Teva, Mylan, and Sandoz to Develop Generic Versions of Daptomycin. https://www.bloomberg.com/news/articles/2022-02-16/teva-mylan-and-sandoz-to-develop-generic-versions-of-daptomycin.
[3] DrugPatentWatch.com. 2022. Daptomycin - patents, news, and analysis. https://www.drugpatentwatch.com/DrugDetails.aspx?DrugId=1641.
Sources cited:
1. Pfizer. 2022. Cubicin (daptomycin) Prescribing Information.
2. Bloomberg. 2022. Teva, Mylan, and Sandoz to Develop Generic Versions of Daptomycin.
3. DrugPatentWatch.com. 2022. Daptomycin - patents, news, and analysis.